KRAS and lung adenocarcinoma: Among the three groups, we evaluated only patients with stage IIIB–IV lung adenocarcinoma who had EGFR mutations (n = 126), KRAS mutations (n = 35), or ALK rearrangements (n = 47) to avoid the influence of confounding factors such as tissue type and staging.